| Australian Clinical Labs Limited (ACL) ORDINARY FULLY PAID |
Health Care |
$525 |
Update - Notification of buy-back - ACL
|
8 Dec 2025 8:45AM |
$2.820 |
$2.730 |
fallen by
3.19%
|
|
| Chalice Mining Limited (CHN) ORDINARY FULLY PAID |
Materials |
$837 |
Gonneville Project PFS - Teleconference and Webcast
|
8 Dec 2025 8:44AM |
$1.750 |
$2.150 |
risen by
22.86%
|
|
| Novatti Group Limited (NOV) ORDINARY FULLY PAID |
Information Technology |
$19 |
AUDC raises $5m in its Pre-Series A round
|
8 Dec 2025 8:44AM |
$0.032 |
$0.031 |
fallen by
3.13%
|
|
NOV - Price-sensitive ASX Announcement
Full Release
Key Points
- AUDC raised $5m in Pre-Series A at A$0.80 per share.
- Novatti holds 20 million shares in AUDC, retaining a 45% interest.
- Novatti's interest in AUDC is now valued at $16m, up from $7m.
- The investment round was led by a large global institutional investor.
- AUDD became the first Australian Dollar stablecoin on Coinbase.
- Novatti's CEO, Mark Healy, highlighted the strategic value created from AUDD.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Hansen Technologies Limited (HSN) ORDINARY FULLY PAID |
Information Technology |
$1,082 |
Notification of cessation of securities - HSN
|
8 Dec 2025 8:43AM |
$5.510 |
$5.300 |
fallen by
3.81%
|
|
| Zip Co Limited (ZIP) ORDINARY FULLY PAID |
Financials |
$4,257 |
Update - Notification of buy-back - ZIP
|
8 Dec 2025 8:42AM |
$2.980 |
$3.350 |
risen by
12.42%
|
|
| AMCIL Limited (AMH) ORDINARY FULLY PAID |
Financials |
$319 |
Update - Notification of buy-back - AMH
|
8 Dec 2025 8:42AM |
$1.040 |
$1.010 |
fallen by
2.88%
|
|
| National Storage REIT (NSR) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$3,847 |
NSR enters into Scheme Implementation Deed
|
8 Dec 2025 8:40AM |
$2.730 |
$2.740 |
risen by
0.37%
|
|
| Ariadne Australia Limited (ARA) ORDINARY FULLY PAID |
Industrials |
$101 |
Update - Notification of buy-back - ARA
|
8 Dec 2025 8:40AM |
$0.500 |
$0.520 |
risen by
4%
|
|
| Chalice Mining Limited (CHN) ORDINARY FULLY PAID |
Materials |
$837 |
Gonneville Project - Pre-Feasibility Study Presentation
|
8 Dec 2025 8:38AM |
$1.750 |
$2.150 |
risen by
22.86%
|
|
| Paragon Care Limited (PGC) ORDINARY FULLY PAID |
Health Care |
$364 |
Change of Director's Interest Notice
|
8 Dec 2025 8:35AM |
$0.260 |
$0.220 |
fallen by
15.38%
|
|
| Ironbark Balanced Income Limited (IBC) ORDINARY FULLY PAID |
Financials |
$45 |
Update - Notification of buy-back - IBC
|
8 Dec 2025 8:35AM |
$0.435 |
$0.440 |
risen by
1.15%
|
|
| Altitude Minerals Ltd (ATT) ORDINARY FULLY PAID |
Materials |
$8 |
Drilling Commenced at Cu-Au Porphyry Drill Target
|
8 Dec 2025 8:35AM |
$0.024 |
$0.024 |
fallen by
0%
|
|
ATT - Price-sensitive ASX Announcement
Full Release
Key Points
- Drilling has commenced to test the T55 Cu-Au Porphyry Target in the interpreted NW extension of the Macquarie Arc, NSW.
- $80,000 NSW Government drilling grant awarded under the Critical Minerals and High-Tech Metals Exploration Program.
- Grant will contribute 40% of the cost for the 500m deep rotary mud and diamond core tail drill hole.
- Drilling expected to take two weeks with assays expected in early Q1, 2026.
- Program fully funded following a successful $2.5m placement.
- Altitude holds an Option to Earn-in agreement with project owner Nimrod Resources for up to a 75% interest in the Project.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Critical Resources Limited (CRR) ORDINARY FULLY PAID |
Materials |
$24 |
Canadian Govt Relations Firm to Accelerate Mavis Lake
|
8 Dec 2025 8:34AM |
$0.008 |
$0.008 |
fallen by
0%
|
|
CRR - Price-sensitive ASX Announcement
Full Release
Key Points
- Engagement of Pathway Group to support Mavis Lake Lithium Project.
- Pathway Group to provide strategic counsel and government engagement.
- Focus on unlocking government funding and strengthening stakeholder relationships.
- Mavis Lake positioned as a major lithium source for Canada and North America.
- Strategic location benefits include proximity to key markets and robust infrastructure.
- Strong government and community support for critical minerals development.
- Project advancement supported by Ontario's stable regulatory environment.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Tribeca Global Natural Resources Limited (TGF) ORDINARY FULLY PAID |
Financials |
$179 |
Update - Notification of buy-back - TGF
|
8 Dec 2025 8:34AM |
$2.110 |
$2.420 |
risen by
14.69%
|
|
| PPK Group Limited (PPK) ORDINARY FULLY PAID |
Materials |
$42 |
Final Director's Interest Notice - Marc Fenton
|
8 Dec 2025 8:33AM |
$0.385 |
$0.465 |
risen by
20.78%
|
|
| G8 Education Limited (GEM) ORDINARY FULLY PAID |
Consumer Discretionary |
$529 |
Update - Notification of buy-back - GEM
|
8 Dec 2025 8:33AM |
$0.705 |
$0.685 |
fallen by
2.84%
|
|
| Noviqtech Limited (NVQ) ORDINARY FULLY PAID |
Information Technology |
$6 |
NVQ, Eco-Markets Australia & Hashgraph- Reef Registry 2.0
|
8 Dec 2025 8:33AM |
$0.022 |
$0.020 |
fallen by
9.09%
|
|
NVQ - Price-sensitive ASX Announcement
Full Release
Key Points
- NoviqTech partners with Eco-Markets Australia and The Hashgraph Group for Reef Credit Registry 2.0.
- The registry will leverage blockchain technology for transparency and scalability.
- Supported by a $160,000 grant from The Hashgraph Association.
- Phase 1 focuses on the delivery of a Minimum Viable Product (MVP) by mid-2026.
- Future phases aim to expand registry capabilities and support additional programs.
- The Hashgraph Group will oversee project coordination and scope management.
- NoviqTech's Carbon Central platform will be integrated into registry operations.
- Registry 2.0 aims to support a wide range of environmental credit programs beyond Reef Credits.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Evergold Minerals Limited (EG1) ORDINARY FULLY PAID |
Materials |
$8 |
New assay results confirm gold prospectivity at Bynoe, NT
|
8 Dec 2025 8:33AM |
$0.037 |
$0.030 |
fallen by
18.92%
|
|
EG1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Re-assays from 2024 RC drilling confirmed gold mineralisation with notable intersections.
- Identified structural corridors are comparable to those hosting nearby multi-million-ounce deposits.
- Field work uncovered historical gold workings, reinforcing the project's gold potential.
- Auger re-assays are in progress to refine gold distribution understanding.
- A high-resolution geophysical campaign is planned for 2026.
- The Bynoe Project's gold focus is a strategic shift from initial lithium exploration.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ophir High Conviction Fund (OPH) ORDINARY UNITS FULLY PAID |
Financials |
$699 |
Weekly NTA 05.12.2025
|
8 Dec 2025 8:33AM |
$3.170 |
$3.140 |
fallen by
0.95%
|
|
| DevEx Resources Limited (DEV) ORDINARY FULLY PAID |
Materials |
$102 |
Share Purchase Plan Opens
|
8 Dec 2025 8:33AM |
$0.200 |
$0.170 |
fallen by
15%
|
|
| Jameson Resources Limited (JAL) ORDINARY FULLY PAID |
Materials |
$55 |
Share issue and cleansing notice
|
8 Dec 2025 8:33AM |
$0.079 |
$0.074 |
fallen by
6.33%
|
|
| Chimeric Therapeutics Limited (CHM) ORDINARY FULLY PAID |
Health Care |
$8 |
CDH17 granted FDA Orphan Drug Designation for Gastric Cancer
|
8 Dec 2025 8:33AM |
$0.003 |
$0.002 |
fallen by
33.33%
|
|
CHM - Price-sensitive ASX Announcement
Full Release
Key Points
- Orphan Drug Designation granted by FDA for CHM CDH17 in gastric cancer treatment.
- The designation offers tax credits, fee exemptions, and potential seven-year market exclusivity.
- Ongoing Phase 1/2 trial involves nine treated and ten enrolled patients.
- CHM CDH17 targets CDH17, linked to poor prognosis in common gastrointestinal tumors.
- Chimeric Therapeutics focuses on innovative cell therapies with multiple clinical programs.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| CSL Limited (CSL) ORDINARY FULLY PAID |
Health Care |
$83,427 |
Update - Notification of buy-back - CSL
|
8 Dec 2025 8:33AM |
$184.100 |
$171.960 |
fallen by
6.59%
|
|
| Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID |
Health Care |
$638 |
CLINUVEL expands Singapore RD&I Centre
|
8 Dec 2025 8:33AM |
$12.330 |
$12.710 |
risen by
3.08%
|
|
CUV - Price-sensitive ASX Announcement
Full Release
Key Points
- Clinuvel announces expansion of VALLAURIX RD&I Centre in Singapore.
- The expansion focuses on developing advanced, long-acting peptide therapies.
- Supported by the Singapore Economic Development Board (EDB).
- Five-year strategic investment aimed at global innovation in peptide-based medicine.
- VALLAURIX Centre to enhance formulation and analytical capabilities.
- Expansion aligns with Clinuvel's strategy of vertical integration and innovation.
- Ongoing projects in pharmaceutical formulations to continue without disruption.
- Expansion aims for full commissioning and certification by FY2028.
- The initiative places Clinuvel at the forefront of peptide delivery technologies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ansell Limited (ANN) ORDINARY FULLY PAID |
Health Care |
$5,063 |
Update - Notification of buy-back - ANN
|
8 Dec 2025 8:32AM |
$36.010 |
$35.200 |
fallen by
2.25%
|
|